Chemo-Immunotherapy Rescue for High-Risk Neuroblastoma Patients With Progressive Disease Before High-Dose Chemotherapy: Real-World Data From the SACHA-France Study.

Fiche publication

Date publication

octobre 2025

Journal

Pediatric blood & cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr JANNIER Sarah

Tous les auteurs :
Pasqualini C, Proust S, Schleiermacher G, Gambart M, Jannier S, Petit A, Dupraz C, Thebaud E, Reguerre Y, Ndounga-Diakou LA, Laghouat S, Defachelles AS, Berlanga P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41044876

Résumé

Patients with high-risk neuroblastoma (HR-NBL) who experience disease progression (PD) during first-line treatment prior to high-dose chemotherapy (HDC) represent a rare and understudied subgroup, for whom treatment strategies are poorly defined and prognosis appears to be extremely poor.